Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimonabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 8/20 | 0.73 |
| ▸ | CNR2 | P34972 | 4/20 | 0.73 |
| ▸ | ACHE | P22303 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.72 |
| ▸ | CCKAR | P32238 | 1/20 | 0.72 |
| ▸ | CCKBR | P32239 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimonabant SCHEMBL4008814 | 0.94 | CNR1 (0.82) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL4000793 | 0.93 | CNR1 (0.68) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL13411625 | 0.92 | CNR1 (0.67) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL13411626 | 0.91 | CNR1 (0.87) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL4001384 | 0.87 | CNR1 (0.76) | CNR1CNR2ACHECYP2C9GPR55 | |
| Hydrochloric Acid SCHEMBL3996916 | 0.86 | CNR1 (0.65) | CNR1CNR2ACHECYP2C9GPR55 | |
| Hydrochloric Acid SCHEMBL3998232 | 0.86 | CNR1 (0.70) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL14338883 | 0.86 | CNR1 (0.75) | CNR1CNR2ACHECYP2C9GPR55 | |
| Hydrochloric Acid SCHEMBL4005602 | 0.85 | CNR1 (0.71) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL29835931 | 0.85 | CNR1 (1.00) | CNR1CNR2ACHECYP2C9GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7514068-B2 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007033366-A2 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885ACHE 1435/4885 |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885ACHE 1435/4885 |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885ACHE 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.